Tech · NZ ·
ASP-1929 + Pembrolizumab Shows 28-Month Median OS in HNSCC Study
The Clinical Trial Vanguard · Tech
Published

Read it at the source
The Clinical Trial Vanguard↗We link out rather than republish. The reporting belongs to the publications above; the summary and the search data on this page are ours.







